Skip to main content
Erschienen in: Investigational New Drugs 5/2011

01.10.2011 | SHORT REPORT

Ultraviolet recall dermatitis reaction with sorafenib

verfasst von: Nicolas Magné, Cyrus Chargari, Pierre Auberdiac, Coralie Moncharmont, Yacine Merrouche, Jean-Philippe Spano

Erschienen in: Investigational New Drugs | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Summary

Purpose Recall dermatitis is a rare and poorly understood drug-related event. Activated by exposure to sunlight or Ultraviolet (UV), drug-related phototoxic reactions have been reported with conventional chemotherapy agents or antibiotics. Methods Here, we report the first case of acute dermatologic photo-induced recall reaction secondary to sorafenib in a patient with renal cell carcinoma. Results Four weeks after stopping sorafenib, a patient with renal cell carcinoma developed an acute erythematous and papulomatous eruption restricted to the hands after prolonged solar exposure. The erythematous region was very well demarcated, mimicking the cutaneous syndrome that the patient had presented at time he was receiving sorafenib. Conclusions The suppression of the phototoxic reaction by corticosteroids strongly suggests that the immune system may have an important function in photo-recall reactions.
Literatur
1.
Zurück zum Zitat Azria D, Magné N, Zouhair A et al (2005) Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 31:555–570PubMedCrossRef Azria D, Magné N, Zouhair A et al (2005) Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 31:555–570PubMedCrossRef
2.
Zurück zum Zitat Badger J, Kang S, Uzieblo A, Srinivas S (2005) Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 23:7224–7225PubMedCrossRef Badger J, Kang S, Uzieblo A, Srinivas S (2005) Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 23:7224–7225PubMedCrossRef
3.
Zurück zum Zitat Borroni G, Vassallo C, Brazzelli V et al (2004) Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol 26:213–216PubMedCrossRef Borroni G, Vassallo C, Brazzelli V et al (2004) Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol 26:213–216PubMedCrossRef
4.
Zurück zum Zitat Camidge DR, Kunkler IH (2000) Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. Clin Oncol 12:272–273 Camidge DR, Kunkler IH (2000) Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. Clin Oncol 12:272–273
5.
Zurück zum Zitat Chung C, Dawson LA, Joshua AM, Brade AM (2010) Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 21:206–209PubMedCrossRef Chung C, Dawson LA, Joshua AM, Brade AM (2010) Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 21:206–209PubMedCrossRef
6.
Zurück zum Zitat Cho S, Breedlove JJ, Gunning ST (2008) Radiation recall reaction induced by levofloxacin. J Drugs Dermatol 7:64–67PubMed Cho S, Breedlove JJ, Gunning ST (2008) Radiation recall reaction induced by levofloxacin. J Drugs Dermatol 7:64–67PubMed
7.
Zurück zum Zitat Dawson GA, Brown SI, Tellefsen L (2009) A drug-related phototoxic réaction and its possible Relationship to a radiation-induced skin réaction. Oncologist 14:303–306PubMedCrossRef Dawson GA, Brown SI, Tellefsen L (2009) A drug-related phototoxic réaction and its possible Relationship to a radiation-induced skin réaction. Oncologist 14:303–306PubMedCrossRef
8.
Zurück zum Zitat Ee HL, Yosipovitch G (2003) Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 207:196–198PubMedCrossRef Ee HL, Yosipovitch G (2003) Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 207:196–198PubMedCrossRef
9.
Zurück zum Zitat Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD (2007) Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 56:494–499PubMedCrossRef Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD (2007) Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 56:494–499PubMedCrossRef
10.
Zurück zum Zitat Kodym E, Kalinska R, Ehringfeld C, Sterbik-Lamina A, Kodym R, Hohenberg G (2005) Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 28:18–21PubMedCrossRef Kodym E, Kalinska R, Ehringfeld C, Sterbik-Lamina A, Kodym R, Hohenberg G (2005) Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 28:18–21PubMedCrossRef
11.
Zurück zum Zitat Magné N, Benezery K, Otto J, Namer M, Lagrange JL (2002) Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature. Cancer Radiothér 6:281–284PubMed Magné N, Benezery K, Otto J, Namer M, Lagrange JL (2002) Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature. Cancer Radiothér 6:281–284PubMed
12.
Zurück zum Zitat Pierfitte C, Royer RJ, Moore N et al (2000) The link between sunshine and phototoxicity of sparfloxacin. Br J Clin Pharmacol 49:609–612PubMedCrossRef Pierfitte C, Royer RJ, Moore N et al (2000) The link between sunshine and phototoxicity of sparfloxacin. Br J Clin Pharmacol 49:609–612PubMedCrossRef
Metadaten
Titel
Ultraviolet recall dermatitis reaction with sorafenib
verfasst von
Nicolas Magné
Cyrus Chargari
Pierre Auberdiac
Coralie Moncharmont
Yacine Merrouche
Jean-Philippe Spano
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 5/2011
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9476-5

Weitere Artikel der Ausgabe 5/2011

Investigational New Drugs 5/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.